Massimiliano Fabbiani is Associate Professor of Infectious Diseases at the Department of Medical Biotechnologies of the University of Siena. His research activity is mainly focused on HIV infection and antiretroviral therapy. In particular, he has participated in clinical trials on antiretroviral therapy and has conducted studies on the efficacy and tolerability of antiretroviral therapy, on the clinical pharmacology of antiretroviral drugs, on the epidemiology and resistance mechanisms of HIV, on adherence to therapy and on comorbidities during HIV infection (with a particular focus on HIV-related neurocognitive disorders). He has also studied the response to vaccinations (anti-influenza, anti-SARS-CoV-2, anti-pneumococcus) in subjects with and without HIV infection. Among the topics covered by his research activities are also infections by hepatitis viruses (HAV, HBV, HCV), SARS-CoV-2 infection, bacterial and fungal infections.
FABBIANI MASSIMILIANO
Presentation
Office hours
Every day by appointment.
Policlinico Le Scotte, IV lotto, piano 0
Curriculum Vitae
Teaching activities
Completion accademic year: 2025/2026
Course year: 1
First cycle degree (DM 270)
ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES
A.Y. 2025/2026
Completion accademic year: 2024/2025
Course year: 1
First cycle degree (DM 270)
ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES
A.Y. 2024/2025
Completion accademic year: 2023/2024
Course year: 1
First cycle degree (DM 270)
ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES
A.Y. 2023/2024
Research
Ultime pubblicazioni:
- Giuliano, G., Hankache, G., Sambo, M., Cusi, M.G., Lazzerini, P.E., Gennari, L., et al. (2025). Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: epidemiology, clinical features and outcomes in the era of antimicrobial resistance. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 44, 116-126 [10.1016/j.jgar.2025.06.006]. - view more
- Rossetti, B., Ferrara, M., Taramasso, L., Bai, F., Lombardi, F., Ciccarelli, N., et al. (2025). Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial. INFECTIOUS DISEASES AND THERAPY, 14(1), 293-304 [10.1007/s40121-024-01083-1]. - view more
- Ciabattini, A., Pettini, E., Fiorino, F., Polvere, J., Lucchesi, S., Coppola, C., et al. (2025). Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses. EBIOMEDICINE, 113(105577) [10.1016/j.ebiom.2025.105577]. - view more
- Sambo, M., Bailoni, A., Mariani, F., Granai, M., Calomino, N., Mancini, V., et al. (2025). Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV. DIAGNOSTICS, 15(2) [10.3390/diagnostics15020198]. - view more
- Ancillotti, L., De Vivo, C., Antonio Bellini, M., De Lalla, A., Vannuzzi, L., Mazzei, M.A., et al. (2024). Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche. In Abstract book XXIII Congresso Nazionale SIMIT (Società Italiana di Malattie Infettive e Tropicali). - view more